ICE和GDP方案治疗复发、难治性弥漫大B细胞淋巴瘤的临床观察

Clinical Observation of ICE and GDP Regimens in the Treatment of Recurrent or Refractory Diffuse Large B-cell Lymphoma

目的观察ICE和GDP方案治疗复发、难治性弥漫大B细胞淋巴瘤(DLBCL)的临床疗效。方法选取2014年1月-2017年1月我院收治的60例复发、难治性DLBCL患者为对象,按随机数字表法均分为对照组和实验组各30例,对照组及实验组分别给予ICE、GDP方案进行治疗,比较两组治疗后的临床疗效及不良反应。结果观察组化疗后患者出现总不良反应率为60.00%,明显低于对照组的83.33%(P<0.05);两组化疗后临床疗效无明显差异。结论 ICE和GDP方案治疗复发、难治性DLBCL的临床疗效相当,后者不良反应较轻,可以更好的用于老年患者及合并心脏疾病的患者,值得在临床上进一步推广。

Objective To observe the clinical efficacy of ICE and GDP regimens in the treatment of recurrent or refractory diffuse large B-cell lymphoma(DLBCL).Methods 60 cases of patients with recurrent or refractory DLBCL who were admitted to our hospital from January 2014 to January 2017 were selected for the study and were divided into control group and experimental group according to the random number table method.Control group was given ICE chemotherapy regimen,and experimental group was treated with GDP chemotherapy regimen.The clinical efficacy and adverse reactions after treatment were compared between the two groups.Results The total adverse reaction rate in observation group after chemotherapy was,which was significantly lower than that in control group(60.00%vs 83.33%)(P<0.05).There was no significant difference in clinical efficacy between the two groups after chemotherapy.Conclusion ICE and GDP regimens can have similar clinical efficacy in the treatment of recurrent or refractory DLBCL,but the latter one has less adverse reactions and can be better used in elderly patients and patients with combined heart disease,therefore the latter one is worthy of further promotion in clinical practice.